Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 74Pancreatic Neoplasms 54Carcinoma, Non-Small-Cell Lung 29Triple Negative Breast Neoplasms 27Neoplasm Metastasis 16Squamous Cell Carcinoma of Head and Neck 15Ovarian Neoplasms 12Neoplasms 12Lung Neoplasms 11Esophageal Squamous Cell Carcinoma 11Stomach Neoplasms 10Esophageal Neoplasms 10Head and Neck Neoplasms 9Uterine Cervical Neoplasms 7Melanoma 7Cholangiocarcinoma 7Small Cell Lung Carcinoma 6Recurrence 6Sarcoma 5Pancreatic Adenocarcinoma 5Inflammatory Breast Neoplasms 5Fallopian Tube Neoplasms 5Urinary Bladder Neoplasms 4Colorectal Neoplasms 4Advanced Pancreatic Cancer 4Carcinoma, Transitional Cell 3Carcinoma, Ovarian Epithelial 3Breast Neoplasms, Male 3Adenocarcinoma 3Uveal Melanoma 2

Interventions

titanium silicide 1mitazalimab 1irinotecan sucrosofate 1devimistat 1S 1 (combination) 1PEGPH20 1Oxaliplatin 1Irinotecan 1Gemcitabine 1Escitalopram 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Pancreatic Ductal Adenocarcinoma × Albumin-Bound Paclitaxel × Clear all
NCT04134468 2020-01-31

MRI Effects of Pegvorhyaluronidase Alfa (PEGPH20) in Pancreatic Ductal Adenocarcinoma

Abramson Cancer Center at Penn Medicine

Phase 2 Withdrawn
Gastrointestinal

Pancreatic Ductal Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡